神经内分泌肿瘤68Ga-DOTA生长抑素受体靶向肽与18F-DOPA PET/CT显像指南
该指南由EANM组织专家修订更新,旨在帮助核医学医师推荐、执行、报告和解读生长抑素受体PET/CT(使用68Ga-DOTA偶联肽)及18F-DOPA显像在各类神经内分泌肿瘤中的应用,整合了该领域近期相关文献。
要点
- 指南适用于神经内分泌肿瘤的68Ga-DOTA-生长抑素受体PET/CT及18F-DOPA显像。
- 指南目的是辅助核医学医师推荐、执行、报告和解读上述显像结果。
- 本次为对EANM既往68Ga偶联肽PET/CT肿瘤显像程序指南的修订更新。
核心结论
- 该指南旨在帮助核医学医师推荐、执行、报告和解读使用68Ga-DOTA偶联肽的生长抑素受体PET/CT及18F-DOPA显像在各类神经内分泌肿瘤中的结果。
- EANM既往关于68Ga偶联肽PET/CT肿瘤显像的程序指南已结合该领域近期相关文献及知名专家贡献进行修订更新。
研究设计与样本
- 本指南由EANM组织专家对既往68Ga偶联肽PET/CT肿瘤显像程序指南进行修订和更新,整合了该领域近期相关文献及知名专家的贡献。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE & METHODS: Neuroendocrine neoplasms are a heterogenous group of tumours, for which nuclear medicine plays an important role in the diagnostic work-up as well as in the targeted therapeutic options. This guideline is aimed to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin receptor (SSTR) PET/CT imaging using 68Ga-DOTA-conjugated peptides, as well as 18F-DOPA imaging for various neuroendocrine neoplasms. RESULTS & CONCLUSION: The previous procedural guideline by EANM regarding the use PET/CT tumour imaging with 68Ga-conjugated peptides has been revised and updated with the relevant and recent literature in the field with contribution of distinguished experts.
引用
- Bozkurt MF, Virgolini I, Balogova S, et al. Guideline for PET/CT imaging of neuroendocrine neoplasms with 68Ga-DOTA-conjugated somatostatin receptor targeting peptides and 18F-DOPA. Eur J Nucl Med Mol Imaging. 2017. PMID: 28547177. doi:10.1007/s00259-017-3728-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。